Editorial

Imaging the Beta-Cell Mass: Why and How

Frantisek Saudek¹, Carl-Henrik Brogren², Srirang Manohar³

Manuscript submitted May 21, 2008; accepted May 29, 2008.

Keywords: diabetes, beta-cell, noninvasive imaging, IC2, islet transplantation, photoacoustic, MRI, PET

Abstract

Diabetes is a disorder characterized by beta-cell loss or exhaustion and insulin deficiency. At present, knowledge is lacking on the underlying causes and for the therapeutic recovery of the beta-cell mass. A better understanding of diabetes pathogenesis could be obtained through exact monitoring of the fate of beta-cells under disease and therapy conditions. This could pave the way for a new era of intervention by islet replacement and regeneration regimens. Monitoring the beta-cell mass requires a reliable method for noninvasive in vivo imaging. Such a method is not available at present due to the lack of a beta-cell-specific contrast agent. The only existing method to monitor islet cells in vivo consists of labeling islet transplants with iron nanoparticles prior to transplantation and visualization of the transplanted islets by magnetic resonance imaging (MRI). Therefore, accurate assessment of the native beta-cell mass is still limited to autopsy studies. Endeavors to find a biological structure specific for beta-cells led to the discovery of potential candidates that have been tested for noninvasive imaging. Among them are the ligand to the vesicular monoamine transporter type 2 (VMAT-2), which is called dihydrotetrabenazine (DTBZ), antibodies to zinc transporter (ZnT-8) and the monoclonal antibody IC2. While DTBZ and antibodies to ZnT-8 showed binding activities to more than beta-cells, the anti-IC2 monoclonal antibody showed binding properties exclusively to insulin-producing beta-cells. This effect was demonstrated in many previous investigations, and has been further substantiated more recently. Thus, at present, IC2 seems to be the only useful marker for noninvasive functional imaging of native beta-cells. Experiments with a radioisotope-chelated IC2 structure on pancreas ex vivo showed that the tracer specifically bound to the beta-cell surface and could be detected by nuclear imaging. In the near future, these promising findings may offer a new way to monitor the beta-cell mass in vivo under disease and therapy conditions so that we can learn more about diabetes pathogenesis and options for disease prevention.

Fulltext: HTML , PDF (1.3 MB)

This article has been cited by other articles:

	Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model Liu G, Dou S, Cheng D, Leif J, Rusckowski M, Streeter PR, Shultz LD, Hnatowich DJ, Greiner DL Mol Pharm 2011. 8(3):767-773
	Type 1 diabetes: etiology, immunology, and therapeutic strategies Van Belle TL, Coppieters KT, Von Herrath MG Physiol Rev 2011. 91(1):79-118
	Assessment of human islet labeling with clinical grade iron nanoparticles prior to transplantation for graft monitoring by MRI Ris F, Lepetit-Coiffe M, Meda P, Crowe LA, Toso C, Armanet M, Niclauss N, Parnaud G, Giovannoni L, Bosco D, Morel P, Vallee JP, Berney T Cell Transplant 2010. 19(12):1573-1585
	Pancreatic beta cell mass PET imaging and quantification with [(11)C]DTBZ and [ (18)F]FP-(+)-DTBZ in rodent models of diabetes Singhal T, Ding YS, Weinzimmer D, Normandin MD, Labaree D, Ropchan J, Nabulsi N, Lin SF, Skaddan MB, Soeller WC, Huang Y, Carson RE, Treadway JL, Cline GW Mol Imaging Biol 2010. Sep 8, epub ahead of print
	Rat pancreas uptake of (11)C dihydrotetrabenazine stereoisomers Kilbourn MR Nucl Med Biol 2010. 37(8):869-871
	Preparation of (111)In-DTPA morpholino oligomer for low abdominal accumulation Liu G, Dou S, Rusckowski M, Greiner D, Hnatowich D Appl Radiat Isot 2010. 68(9):1709-1714
	The role of transmembrane protein 27 (TMEM27) in islet physiology and its potential use as a beta cell mass biomarker Altirriba J, Gasa R, Casas S, Ramirez-Bajo MJ, Ros S, Gutierrez-Dalmau A, Ruiz de Villa MC, Barbera A, Gomis R Diabetologia 2010. 53(7):1406-1414
	Imaging Pancreatic Beta-Cells: Update from the 4th Workshop of the National Institutes of Health, Washington DC, April 2009 Ris F, Crowe L, Berney T Rev Diabet Stud 2009. 6(4):279-282
	Mouse models for type 1 diabetes Van Belle TL, Taylor P, von Herrath MG Drug Discov Today Dis Models 2009. 6(2):41-45
	Noninvasive imaging of pancreatic beta cells Malaisse WJ, Louchami K, Sener A Nat Rev Endocrinol 2009. 5(7):394-400
	Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, Bartenstein P, Pöpperl G Eur J Nucl Med Mol Imaging 2009. 36(5):765-770
	Zinc signalling and subcellular distribution: emerging targets in type 2 diabetes Mocchegiani E, Giacconi R, Malavolta M Trends Mol Med 2008. 14(10):419-428